Search research articles
Contact Us
Filters
Showing results (21-30 of 142) with videos related to
Page
of 15
Sort By:
The Journal of Cell Biology
|
November 26, 2003
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
Sven Christian, Jan Pilch, Maria E Akerman, et al.
Pediatric Blood & Cancer
|
May 11, 2006
Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells
Sanna-Maria Kivivuori, Sanna Siitonen, Kimmo Porkka, et al.
Experimental Hematology
|
September 28, 2010
Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy
Sari E Jalkanen, Jukka Vakkila, Anna Kreutzman, et al.
Haematologica
|
October 2, 2009
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)
Satu Mustjoki, Sari Hernesniemi, Auvo Rauhala, et al.
Annals of Medicine
|
February 12, 2014
Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations
Hanna L M Rajala, Kimmo Porkka, Jaroslaw P Maciejewski, et al.
Cancer
|
November 20, 2009
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
Kimmo Porkka, H Jean Khoury, Ronald L Paquette, et al.
Duodecim; Laaketieteellinen Aikakauskirja
|
December 15, 2017
Applications of genomic medicine in the treatment of diseases
Kimmo Porkka, Mikko Niemi, Elli Leppä, et al.
Plos One
|
February 6, 2014
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy
Mette Ilander, Anna Kreutzman, Peter Rohon, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 3, 2026
Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland
Tuija Tapaninen, Vesa Lindström, Olivia Hölsä, et al.
Blood
|
April 24, 2010
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman, Vesa Juvonen, Veli Kairisto, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 142) with videos related to
Sort By:
Page
of 15
The Journal of Cell Biology
|
November 26, 2003
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
Sven Christian, Jan Pilch, Maria E Akerman, et al.
Pediatric Blood & Cancer
|
May 11, 2006
Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells
Sanna-Maria Kivivuori, Sanna Siitonen, Kimmo Porkka, et al.
Experimental Hematology
|
September 28, 2010
Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy
Sari E Jalkanen, Jukka Vakkila, Anna Kreutzman, et al.
Haematologica
|
October 2, 2009
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)
Satu Mustjoki, Sari Hernesniemi, Auvo Rauhala, et al.
Annals of Medicine
|
February 12, 2014
Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations
Hanna L M Rajala, Kimmo Porkka, Jaroslaw P Maciejewski, et al.
Cancer
|
November 20, 2009
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
Kimmo Porkka, H Jean Khoury, Ronald L Paquette, et al.
Duodecim; Laaketieteellinen Aikakauskirja
|
December 15, 2017
Applications of genomic medicine in the treatment of diseases
Kimmo Porkka, Mikko Niemi, Elli Leppä, et al.
Plos One
|
February 6, 2014
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy
Mette Ilander, Anna Kreutzman, Peter Rohon, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 3, 2026
Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland
Tuija Tapaninen, Vesa Lindström, Olivia Hölsä, et al.
Blood
|
April 24, 2010
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman, Vesa Juvonen, Veli Kairisto, et al.
Page
of 15